Biotech Values

[dumaflotchie]

It seems to me that MNTA receives the equivalent of half it's market cap in Baxter support in this FoB development which essentially negates the drain on its capital during the next 3-4 year development period. That doesn't seem unwise under the circumstances.

Further, there was no necessity to do a deal at this moment in time so I rather think MNTA was satisfied with the deal as it stands. It isn't as though this company was on its last stand without capital coming into its coffers. Some here seem to imply a near desperation to do a FoB deal but that just doesn't jive with their circumstances.

They are establishing many truly legitimate shots on goal.